Tao Yi, Song Licheng, Fu Han, Zhang Wei, Song Yuwei, Liu Hongxiang, Xie Lixin, Wang Kaifei
College of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital, Beijing, China.
Medical School of Chinese PLA, Beijing, China.
Ann Transl Med. 2022 Jan;10(1):7. doi: 10.21037/atm-21-5465.
To analyze the clinical value of microbiological rapid on-site evaluation (M-ROSE) in the respiratory intensive care unit (RICU) and its impact on the prognosis of critically ill patients.
We retrospectively included patients who underwent bedside bronchoalveolar lavage in the RICU of Chinese People's Liberation Army (PLA) General Hospital between January 2017 and December 2020. The patients were divided into M-ROSE and control groups according to whether bedside M-ROSE was performed with to guide the treatment, and for control group, routine treatments were administrated based on all the clinical information. The basic information, treatment methods, test indicators, and prognostic evaluation of the patients were collected and analyzed.
A total of 242 patients were enrolled, including 130 patients in the M-ROSE group and 112 patients in the control group. The inflammatory indicators of the patients in the M-ROSE group decreased significantly faster after admission than those of patients in the control group, and the patients in the M-ROSE group used significantly more types of antibiotics [5 (3.0, 5.0)] than those in the control group [3 (2.0, 4.0)] (P<0.05). Among the patients who were on invasive mechanical ventilation, the mortality rate of the M-ROSE group was significantly lower than that of the control group (P<0.05). The coincidence rate of the M-ROSE results with metagenomic next-generation sequencing (mNGS) results was 66.2%, which was higher than the coincidence rate of other laboratory results. In addition, the M-ROSE reports were available significantly faster than the smear, culture, and mNGS results.
M-ROSE has high diagnostic value for lower respiratory tract pathogens. The application of M-ROSE in the RICU can help to promote a decrease in patients' inflammation levels and reduce the mortality of patients on invasive mechanical ventilation.
分析微生物快速现场评估(M-ROSE)在呼吸重症监护病房(RICU)的临床价值及其对危重症患者预后的影响。
回顾性纳入2017年1月至2020年12月在中国人民解放军总医院RICU接受床旁支气管肺泡灌洗的患者。根据是否进行床旁M-ROSE以指导治疗将患者分为M-ROSE组和对照组,对照组根据所有临床信息进行常规治疗。收集并分析患者的基本信息、治疗方法、检测指标和预后评估。
共纳入242例患者,其中M-ROSE组130例,对照组112例。M-ROSE组患者入院后炎症指标下降速度明显快于对照组,且M-ROSE组患者使用的抗生素种类明显多于对照组[5(3.0,5.0)种比3(2.0,4.0)种](P<0.05)。在接受有创机械通气的患者中,M-ROSE组的死亡率明显低于对照组(P<0.05)。M-ROSE结果与宏基因组下一代测序(mNGS)结果的符合率为66.2%,高于其他实验室结果的符合率。此外,M-ROSE报告比涂片、培养和mNGS结果获得明显更快。
M-ROSE对下呼吸道病原体具有较高的诊断价值。M-ROSE在RICU中的应用有助于促进患者炎症水平下降,降低接受有创机械通气患者的死亡率。